Log in to save to my catalogue
Log in to save to my catalogue

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised contr...

| Ask | Become a Library member

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised contr...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1093452644

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

About this item

Publication information

Publisher

England: Elsevier Ltd

Subjects

More information

Scope and Contents

Contents

Summary Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600 -mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients with BRAFV600E -mutated metastatic melanoma. Methods We enrolled patients in this open-label phase 3...

Alternative Titles

Full title

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1093452644

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1093452644

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(12)60868-X

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections